KR101840501B1 - 망막 질환을 치료하기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그 - Google Patents

망막 질환을 치료하기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그 Download PDF

Info

Publication number
KR101840501B1
KR101840501B1 KR1020137009503A KR20137009503A KR101840501B1 KR 101840501 B1 KR101840501 B1 KR 101840501B1 KR 1020137009503 A KR1020137009503 A KR 1020137009503A KR 20137009503 A KR20137009503 A KR 20137009503A KR 101840501 B1 KR101840501 B1 KR 101840501B1
Authority
KR
South Korea
Prior art keywords
methyl
ethyl
imidazol
benzyl ester
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137009503A
Other languages
English (en)
Korean (ko)
Other versions
KR20140003407A (ko
Inventor
모하메드 아이. 디바스
다니엘 더블유. 길
켄 차우
리밍 왕
마이클 이. 가스트
존 이. 도넬로
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101840501(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20140003407A publication Critical patent/KR20140003407A/ko
Application granted granted Critical
Publication of KR101840501B1 publication Critical patent/KR101840501B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137009503A 2010-09-16 2011-09-16 망막 질환을 치료하기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그 Active KR101840501B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16
US61/383,370 2010-09-16
PCT/US2011/051926 WO2012037453A1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

Publications (2)

Publication Number Publication Date
KR20140003407A KR20140003407A (ko) 2014-01-09
KR101840501B1 true KR101840501B1 (ko) 2018-05-04

Family

ID=44675870

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020137009503A Active KR101840501B1 (ko) 2010-09-16 2011-09-16 망막 질환을 치료하기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020207021626A Active KR102354097B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020207011231A Active KR102139905B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020137009506A Active KR101952457B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020137009505A Withdrawn KR20140005154A (ko) 2010-09-16 2011-09-16 피부 질환과 장애를 치료하기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020137009502A Active KR101840500B1 (ko) 2010-09-16 2011-09-16 안압을 낮추기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020197004880A Active KR102104760B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그

Family Applications After (6)

Application Number Title Priority Date Filing Date
KR1020207021626A Active KR102354097B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020207011231A Active KR102139905B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020137009506A Active KR101952457B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020137009505A Withdrawn KR20140005154A (ko) 2010-09-16 2011-09-16 피부 질환과 장애를 치료하기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020137009502A Active KR101840500B1 (ko) 2010-09-16 2011-09-16 안압을 낮추기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020197004880A Active KR102104760B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그

Country Status (28)

Country Link
US (9) US8492557B2 (enExample)
EP (13) EP2616066B1 (enExample)
JP (4) JP6045495B2 (enExample)
KR (7) KR101840501B1 (enExample)
CN (5) CN105412092B (enExample)
AR (4) AR083019A1 (enExample)
AU (4) AU2011301847B2 (enExample)
BR (4) BR112013006352A2 (enExample)
CA (8) CA2811559A1 (enExample)
CL (4) CL2013000736A1 (enExample)
CY (3) CY1121024T1 (enExample)
DK (9) DK3050563T3 (enExample)
ES (10) ES2687420T3 (enExample)
HU (5) HUE048725T2 (enExample)
IL (4) IL225281A0 (enExample)
MX (4) MX2013003009A (enExample)
MY (4) MY168763A (enExample)
NZ (1) NZ608751A (enExample)
PL (7) PL3050563T3 (enExample)
PT (7) PT3050564T (enExample)
RU (4) RU2013116763A (enExample)
SG (4) SG188573A1 (enExample)
SI (5) SI3050564T1 (enExample)
TR (1) TR201909249T4 (enExample)
TW (4) TW201240661A (enExample)
UA (1) UA112973C2 (enExample)
WO (4) WO2012037453A1 (enExample)
ZA (4) ZA201302194B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010093930A1 (en) 2009-02-13 2010-08-19 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
US8492557B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
CA2842866A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
WO2013078151A1 (en) 2011-11-21 2013-05-30 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
CN111386275B (zh) * 2018-08-24 2023-03-10 杭州阿诺生物医药科技有限公司 高活性sting蛋白激动剂
CA3214876A1 (en) * 2021-04-16 2022-10-20 Wenkui Ken Fang Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs
EP4661868A1 (en) * 2023-02-08 2025-12-17 Bausch + Lomb Ireland Limited Alpha-2-adrenergic agonists for improving vision
WO2025179071A1 (en) * 2024-02-20 2025-08-28 Bausch + Lomb Ireland Limited Sustained-release drug delivery compositions for treating ocular diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089132A1 (en) 2008-01-09 2009-07-16 Allergan, Inc. Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
WO2010091209A1 (en) 2009-02-06 2010-08-12 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
WO2010093930A1 (en) 2009-02-13 2010-08-19 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
ES2188649T3 (es) 1993-11-15 2003-07-01 Schering Corp Fenil-alquil-imidazoles como antagonistas del receptor h3.
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
WO2004106307A2 (fr) * 2003-05-27 2004-12-09 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament
WO2005006720A1 (en) * 2003-07-14 2005-01-20 Koninklijke Philips Electronics N.V. Projection device
CA2538445A1 (en) * 2003-09-12 2005-04-21 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
DK1761266T3 (da) * 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
JP2008514601A (ja) * 2004-09-24 2008-05-08 アラーガン、インコーポレイテッド 特異的α２アドレナリン作動剤としての４−（フェニルメチルおよび置換フェニルメチル）−イミダゾール−２−チオン
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8492557B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089132A1 (en) 2008-01-09 2009-07-16 Allergan, Inc. Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
WO2010091209A1 (en) 2009-02-06 2010-08-12 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
WO2010093930A1 (en) 2009-02-13 2010-08-19 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Current Topics in Medicinal Chemistry, vol. 7, no. 2, pp. 163-186 (2007.01.01)

Also Published As

Publication number Publication date
RU2013116403A (ru) 2014-10-27
SG188571A1 (en) 2013-04-30
ES2613509T3 (es) 2017-05-24
IL225278A (en) 2015-11-30
TWI591058B (zh) 2017-07-11
ES2904479T3 (es) 2022-04-05
JP2013541527A (ja) 2013-11-14
EP3078376A1 (en) 2016-10-12
TW201305117A (zh) 2013-02-01
KR20130114140A (ko) 2013-10-16
JP2013540749A (ja) 2013-11-07
ZA201302288B (en) 2013-11-27
EP3050564B1 (en) 2019-09-04
AU2011301901B2 (en) 2016-02-11
HUE048725T2 (hu) 2020-09-28
EP3050563B1 (en) 2018-05-09
AU2011301932C1 (en) 2016-09-01
CA2812191C (en) 2021-04-13
IL225281A0 (en) 2013-06-27
JP2013537237A (ja) 2013-09-30
CA2812197C (en) 2024-01-02
AR083020A1 (es) 2013-01-23
CL2013000735A1 (es) 2013-11-29
PL2616068T3 (pl) 2016-11-30
TW201240661A (en) 2012-10-16
TW201240662A (en) 2012-10-16
PT3050563T (pt) 2018-10-01
RU2013116541A (ru) 2014-10-27
SG188573A1 (en) 2013-04-30
EP2616069B1 (en) 2016-11-16
US8492422B2 (en) 2013-07-23
EP2616068B1 (en) 2016-07-13
HK1185540A1 (en) 2014-02-21
CA2812195A1 (en) 2012-03-22
AU2011301847A1 (en) 2013-05-02
TW201305116A (zh) 2013-02-01
CN103200942A (zh) 2013-07-10
PL3348264T3 (pl) 2020-08-24
US20120122945A1 (en) 2012-05-17
KR101952457B1 (ko) 2019-02-26
EP2616067B1 (en) 2016-05-18
IL225278A0 (en) 2013-06-27
EP3050564A1 (en) 2016-08-03
SI3050564T1 (sl) 2020-02-28
SG188572A1 (en) 2013-04-30
AU2011301932A1 (en) 2013-05-02
EP3338777B1 (en) 2020-02-05
HK1257416A1 (en) 2019-10-18
WO2012037453A1 (en) 2012-03-22
EP2616068A1 (en) 2013-07-24
ES2760920T3 (es) 2020-05-18
HUE039090T2 (hu) 2018-12-28
MY191369A (en) 2022-06-20
US20150148394A1 (en) 2015-05-28
MX2013003004A (es) 2013-06-28
EP3078376B1 (en) 2019-03-27
WO2012037484A1 (en) 2012-03-22
MY161607A (en) 2017-04-28
EP2616066A1 (en) 2013-07-24
MX2013003002A (es) 2013-06-28
KR102354097B1 (ko) 2022-01-20
AU2011301901A1 (en) 2013-05-02
JP6073229B2 (ja) 2017-02-01
EP2616066B1 (en) 2016-07-13
AU2011301932B2 (en) 2016-02-25
KR102104760B1 (ko) 2020-04-27
AU2011301856C1 (en) 2016-09-08
CL2013000736A1 (es) 2013-07-12
SI3338777T1 (sl) 2020-08-31
HUE038698T2 (hu) 2018-11-28
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
BR112013006352A2 (pt) 2016-06-28
EP3636263B1 (en) 2021-11-03
EP3053576A1 (en) 2016-08-10
CA3122745A1 (en) 2012-03-22
HUE049573T2 (hu) 2020-10-28
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28
US20120149746A1 (en) 2012-06-14
PT2616068T (pt) 2016-09-13
SI3053576T1 (sl) 2018-11-30
WO2012037499A1 (en) 2012-03-22
EP3050563A1 (en) 2016-08-03
PL3338777T3 (pl) 2020-07-13
CA3116249A1 (en) 2012-03-22
ES2781681T3 (es) 2020-09-04
AR083018A1 (es) 2013-01-23
HK1185538A1 (zh) 2014-02-21
UA112973C2 (uk) 2016-11-25
EP3053576B1 (en) 2018-05-16
KR20200091507A (ko) 2020-07-30
US20130289088A1 (en) 2013-10-31
KR20190022895A (ko) 2019-03-06
MY173846A (en) 2020-02-24
DK3348264T3 (da) 2020-03-23
KR20140003407A (ko) 2014-01-09
NZ608751A (en) 2015-04-24
US20160354346A1 (en) 2016-12-08
CN105412092A (zh) 2016-03-23
BR112013006320A2 (pt) 2016-06-21
MX2013003009A (es) 2013-06-28
BR112013006355A2 (pt) 2016-06-28
AR083019A1 (es) 2013-01-23
SG188570A1 (en) 2013-04-30
IL225280A0 (en) 2013-06-27
CY1121024T1 (el) 2019-12-11
ES2788051T3 (es) 2020-10-20
US8492557B2 (en) 2013-07-23
TR201909249T4 (tr) 2019-07-22
EP3348264B1 (en) 2020-01-01
US8501796B2 (en) 2013-08-06
CN105412092B (zh) 2020-11-17
DK2616069T3 (en) 2016-12-19
RU2013116405A (ru) 2014-10-27
ES2737230T3 (es) 2020-01-10
DK3050563T3 (en) 2018-08-13
PT3348264T (pt) 2020-04-02
DK3636263T3 (da) 2022-01-10
PT3338777T (pt) 2020-05-06
CA3077732A1 (en) 2012-03-22
CA2812191A1 (en) 2012-03-22
DK3338777T3 (da) 2020-04-20
PT2616069T (pt) 2016-12-06
MX2013003008A (es) 2013-06-28
WO2012037490A1 (en) 2012-03-22
US20130296394A1 (en) 2013-11-07
IL225282A0 (en) 2013-06-27
HK1185541A1 (zh) 2014-02-21
US20120142746A1 (en) 2012-06-07
ES2607084T3 (es) 2017-03-29
DK3078376T3 (da) 2019-06-24
CY1122958T1 (el) 2021-10-29
KR102139905B1 (ko) 2020-07-31
MY168763A (en) 2018-12-04
PL3050563T3 (pl) 2018-12-31
KR20140005154A (ko) 2014-01-14
ZA201302291B (en) 2013-11-27
CA2812197A1 (en) 2012-03-22
PL3053576T3 (pl) 2018-11-30
PT3053576T (pt) 2018-10-08
EP3348264A1 (en) 2018-07-18
KR101840500B1 (ko) 2018-03-20
HK1185539A1 (zh) 2014-02-21
PL2616069T3 (pl) 2017-04-28
JP2013537236A (ja) 2013-09-30
US20120136036A1 (en) 2012-05-31
CA2811559A1 (en) 2012-03-22
EP3636263A1 (en) 2020-04-15
ES2687420T3 (es) 2018-10-25
CY1122809T1 (el) 2021-05-05
PT3050564T (pt) 2019-12-11
CN103221045A (zh) 2013-07-24
EP2616069A1 (en) 2013-07-24
EP2616067A1 (en) 2013-07-24
EP3659600A1 (en) 2020-06-03
CN103209694A (zh) 2013-07-17
EP3338777A1 (en) 2018-06-27
JP6045495B2 (ja) 2016-12-14
CA3079450A1 (en) 2012-03-22
RU2612351C2 (ru) 2017-03-07
DK3053576T3 (en) 2018-08-20
CN103200941A (zh) 2013-07-10
US8853251B2 (en) 2014-10-07
CL2013000733A1 (es) 2013-08-23
US8653123B2 (en) 2014-02-18
AU2011301856A1 (en) 2013-05-02
CN103200941B (zh) 2015-12-16
DK3050564T3 (da) 2019-11-25
DK2616068T3 (en) 2016-08-29
KR20200044147A (ko) 2020-04-28
ES2684055T3 (es) 2018-10-01
HUE047476T2 (hu) 2020-04-28
US20140057958A1 (en) 2014-02-27
SI3050563T1 (sl) 2018-10-30
EP3698789A1 (en) 2020-08-26
CL2013000734A1 (es) 2013-11-08
ES2593612T3 (es) 2016-12-12
SI3348264T1 (sl) 2020-07-31
AU2011301847B2 (en) 2016-02-11
PL3050564T3 (pl) 2020-06-01
ZA201302194B (en) 2013-11-27
ZA201302193B (en) 2013-11-27
BR112013006320B1 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
KR101840501B1 (ko) 망막 질환을 치료하기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
HK40036790A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
HK1185539B (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for treating retinal diseases
HK1257416B (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130415

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160907

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170821

Patent event code: PE09021S01D

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20180115

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180314

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180314

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210226

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20211229

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20221221

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240102

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20241223

Start annual number: 8

End annual number: 8